Retatrutide Clinical Trials: 32 Studies, Results, and Status

By The RX Index Editorial Team · Last verified October 2026

Retatrutide clinical trials span 32 studies listed on ClinicalTrials.gov. Five Phase 3 trials have reported results. In the biggest reported trial, TRIUMPH-1, people assigned the top dose lost 25.0% of their weight on average over 80 weeks, counting everyone randomized. Two records list recruiting studies, and retatrutide is not FDA-approved.¹²³

What changes that picture for you: whether you have type 2 diabetes (the diabetes trials reported smaller average losses), which dose and how long, and how a trial counted people who quit. And the two open studies are narrow. One is a four-year liver study. The other doesn't list Lilly as its sponsor.

Below is every study in one tracker, the head-to-head against Zepbound's medicine with main data collection estimated to end in November 2026, and exactly what to ask a study team before you get your hopes up.⁴

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

RX Index Decision Verdict: Check the research fit before you chase access.

• Best for: adults deciding whether a trial inquiry, a talk with their doctor, or an approved medicine now makes the most sense.
• Not ideal for: anyone looking for a prescription, a seller, or a dosing plan. We don't publish those for an unapproved drug.
• The factor that matters most: a study that matches your condition and a site that's actually screening this week — not the biggest weight-loss headline.

---

Retatrutide clinical trials tracker (checked October 14, 2026)

ClinicalTrials.gov lists 32 studies with retatrutide as an intervention, plus one expanded-access listing. As of October 14, 2026, 21 are completed, 9 are still running but closed to new people, and 2 are listed as recruiting. Of the 14 Phase 3 studies in Lilly's late-stage program, only SYNERGY-Outcomes is recruiting.¹

Think of the program as three families. TRIUMPH tests weight and related health problems, including heart and kidney outcomes. TRANSCEND tests type 2 diabetes; TRANSCEND-CKD studies kidney disease. SYNERGY tests fatty liver disease. Each numbered trial has a main question, like "does it ease knee pain?" or "does the weight stay off?"¹⁵

Status at a glance

Phase 3 studies (all 14)

BMI, or body mass index, is a height-and-weight measure. A1C (also called HbA1c) is a blood test that tracks average blood sugar over the past few months. An SGLT2 inhibitor is another type of diabetes medicine. In these tables, a minus sign means a decrease. The doses are research groups, not instructions for taking retatrutide.

Statuses are for the whole study, not any one site. “~” marks estimated enrollment; future primary-completion dates are estimates, not results-announcement dates. Unless labeled otherwise, weight results are for the 12 mg group using the efficacy analysis, explained below. A1C changes are percentage points. People counts use reported randomized totals where available; the registry lists slightly different totals for TRIUMPH-1 (2,335) and TRIUMPH-3 (1,946). “Not reported” means no result was identified in the sources checked for this page, not that a result cannot exist. Sources: each linked registry record and the primary publications under Sources.

One thing that trips people up: Lilly's own trial pages say "Completed enrollment" for studies that are still running. That means they've stopped taking new people, not that the study is over. TRIUMPH-7 is the example. Older pages listed it as open; its registry record now says Active, not recruiting.⁶

Retatrutide isn't available by ordinary prescription. But the right available GLP-1 isn't the same for everyone — it depends on your state, your insurance and formulary (your plan's drug list), whether you need an FDA-approved or compounded medicine, a shot or a pill, and your budget. Compounded medicines are not FDA-approved.³ Use The RX Index's Find My GLP-1 Path tool to see which path fits you before you choose. It suggests paths and providers; it does not enroll you in a trial or confirm insurance approval.⁷

Phase 2 studies (4)

Phase 1 studies (14)

These early studies test safety and how the body handles the drug, mostly in small groups. Thirteen are completed. One is still running.

For example, choose Type 2 diabetes + Recruiting and the tracker shows no study tagged that way. That does not mean a person with type 2 diabetes cannot join any study: SYNERGY-Outcomes is tagged Liver, and its posted criteria do not exclude type 2 diabetes itself. Its liver-test and other screening rules still apply.¹²

---

What reports next: the retatrutide trial calendar

Three studies have main data-collection dates between August and November 2026: TRANSCEND-T2D-2 (against semaglutide), TRANSCEND-T2D-3 (diabetes with kidney disease), and TRIUMPH-5 (against tirzepatide). Only TRANSCEND-T2D-2's date is marked actual; the other two are estimates. We found no exact results-announcement dates in the sponsor sources checked. Separately, Lilly plans to file for FDA approval in the first quarter of 2027.⁴¹³¹⁴

"Data collection ends" isn't "results day." These registry dates do not set a results-announcement date, and sponsors can revise estimates. Primary completion means the last collection of data needed for the main outcome; follow-up may continue afterward.¹

Why TRIUMPH-5 matters most if you're on Zepbound

It's the direct race between retatrutide and tirzepatide, the medicine in Zepbound and Mounjaro. People from the same study population, randomly assigned under the same rules, with the same finish line. Until it reports, "retatrutide beats Zepbound" is a guess built from separate trials. Our retatrutide vs tirzepatide page shows the closest fair comparison we can make today.⁴

---

Can you join a retatrutide clinical trial?

The two studies listed as recruiting have narrow entry rules. As of October 14, 2026, one is SYNERGY-Outcomes, a Lilly study lasting more than four years for people with high-risk fatty liver disease. The other is a Phase 2 study at one site in China, whose listed sponsor is Hudson Biotech, not Lilly. Every TRIUMPH weight trial in this tracker is closed to new people.¹²¹⁵¹

Here's the honest part. No web page, including this one, can tell you if you'll qualify. The study team decides that at screening. What we can do is help you find out fast, and keep you from wasting a trip.

The one open Lilly study: SYNERGY-Outcomes

SYNERGY-Outcomes studies adults with high-risk metabolic dysfunction-associated steatotic liver disease, or MASLD — fatty liver disease linked to metabolic health problems. Having obesity alone is not enough to get in. The study uses specific liver-test results to find people at higher risk.¹²

Here's what the posted record asks for. This is a screening summary, not a yes or no.

Source: NCT07165028, record updated Oct 8, 2026.

After the main study, eligible people may join an optional two-year extension where everyone gets retatrutide or tirzepatide, even if they had placebo before. That's a possibility, not a promise.¹²

The record lists sites in 35 U.S. states, plus Canada, the UK, Australia, and many other countries. Some are marked "not yet recruiting." A listed site is not the same as an open spot.¹²

Does this sound like a liver condition your doctor has already flagged? Check the study's official contacts before you make travel or treatment plans.

The other "recruiting" listing

NCT07467447 lists a study of several retatrutide doses against placebo, with planned enrollment of 300 adults with obesity or overweight and a weight-related condition, without diabetes. It lists one site: Shenzhen, China. Its sponsor is listed as Hudson Biotech, not Eli Lilly.¹⁵

We could not confirm who supplies this study's retatrutide or whether Lilly is involved. The record's sponsor name alone cannot settle that. Before considering it, ask the hospital to confirm the study's local authorization, ethics approval, drug supplier, and current screening status. We list it for completeness, not as a verified Lilly-access option.¹⁵

A quick self-check before you call anyone

Have these answers ready for the study team. They help you ask the right questions; they do not decide whether you qualify.

1. Are you 18 or older? Both recruiting records require adults. The Hudson record also sets an upper age of 75.¹²¹⁵
2. Have you taken a weight-loss medicine, including Zepbound or Wegovy, in the last 3 months? Rules differ by study. NCT07467447 excludes weight-loss medicines taken within 3 months. The now-closed TRIUMPH-7 record uses 90 days; do not apply that rule to SYNERGY-Outcomes.¹⁵⁶
3. Do you have type 1 diabetes, a history of pancreatitis, or a personal or family history of medullary thyroid cancer? Tell the team. Both recruiting records exclude type 1 diabetes; the Hudson record also lists pancreatitis and thyroid-cancer-related exclusions. Have the team review the exact rules and your history.¹²¹⁵
4. Can you commit to years of visits? The open Lilly study runs about four years.

Never stop a medicine your doctor prescribed to chase a trial spot. Talk to your prescriber and the study team first.

Will you get placebo?

You could receive placebo in studies that include it. A placebo is a look-alike shot without the study medicine. TRIUMPH-3 assigned about half its people to placebo. SYNERGY-Outcomes has placebo groups. Some studies compare retatrutide with another medicine instead (TRIUMPH-5 uses tirzepatide), and TRIUMPH-9 assigns everyone to retatrutide. But those two are closed.^1612417

Ask the site exactly how treatment is assigned in the part you'd join. Read the consent form. An inquiry or screening visit does not promise you retatrutide.

How to contact a study team

Start with the official record. Check its status. Find a site you can actually reach. Then ask that site whether it's screening new people this week. An old city list is not proof of an opening.

You can also call the Lilly Trial Information Center at 1-877-CTLILLY (1-877-285-4559). Outside the U.S., use the country and site list on the study record.¹²

Here's a message you can copy and send. It asks the questions that save you a wasted trip.

Hello, I'm asking about [study name and NCT number]. Is your location screening new participants right now, and is the retatrutide part of the study open? Could you explain the main screening requirements, whether I could get placebo or another medicine, how many in-person visits there are, and who pays for study care and travel? Please also tell me how you handle my current medicines, what happens when the study ends, and the secure way to send any medical records you need.

Looking for a study we haven't listed, or one that's newly posted? Search the official registry and check the date on each record.

What could taking part cost?

Don't assume a trial is free, and don't assume it pays. The study's consent papers, not a directory listing, explain what you or your insurance might owe. We didn't confirm costs or payments for any site.¹⁸

Ask the site how it handles uninsured participants. We have not confirmed an insurance requirement or a payment arrangement for your situation.

If you're very sick and can't join a trial: expanded access

Expanded access is a separate way for some very sick patients to get an investigational medicine outside a trial. It is not a trial or an ordinary retail prescription. Retatrutide's program, NCT07629401, is listed as "Available," but your own doctor has to request it, and you must meet all five rules.

Source: NCT07629401, record updated Aug 6, 2026. Having a medical reason you shouldn't take retatrutide rules you out.

Your treating doctor makes the request. The record sends doctors to Lilly at 1-800-LillyRx (1-800-545-5979) and tells patients to go through their own doctor, not call Lilly. The record says access depends on location, supply, and an individual review. In the U.S., expanded access also requires the applicable FDA and ethics-review permissions before treatment.¹⁹²⁰

For a printable doctor checklist, see our retatrutide availability guide.

---

Can't get into a trial? What you can start now

Without a trial place or approved expanded-access request, waiting is a real choice. It just isn't a treatment plan, because no approval date or official commercial price has been announced. FDA-approved medicines are available now, including tirzepatide (Zepbound), the drug retatrutide is being tested against in TRIUMPH-5.³¹⁴²¹⁴

Say you're 47, your BMI is 38, and you've been on nothing for a year because you were waiting for "the strongest one." Age and BMI alone don't get you into either recruiting study. You can ask your doctor whether a study or expanded access fits your health situation, or discuss an approved option now. Waiting until the next planned milestone is another choice — but Lilly's filing plan is not a promised launch.

Quick check: is your BMI 30 or higher, or 27 or higher with a weight-related condition like high blood pressure? Those are the BMI ranges used in Zepbound's adult weight-management studies. The label covers adults with obesity, or overweight with a weight-related condition, alongside a reduced-calorie diet and more physical activity. A clinician still decides.²¹

Under 18, pregnant or planning pregnancy, living with type 1 diabetes, or with an eating-disorder history? Start with your own clinician before choosing a program. Also discuss any known reason not to take the medicine. Zepbound must not be used with a personal or family history of medullary thyroid cancer, multiple endocrine neoplasia type 2 (MEN 2), or a serious allergy to tirzepatide or its ingredients.²¹

One honest limit: Ro can't get you retatrutide. Legitimate access is through research or a narrowly approved expanded-access request, not an ordinary prescription. What Ro does offer is a free report on insurance coverage for Ozempic pens, Wegovy pens, and Zepbound autoinjector pens. Prior-authorization paperwork is a separate service within its paid membership. Prior authorization is your insurer's review before it agrees to cover treatment — not an approval promised by Ro. If you don't need insurance help, the manufacturers' own cash programs may be simpler.¹⁹²²²³

Ro's membership is $39 for the first month, then $74 to $149 a month depending on the plan. The $74 rate means prepaying 12 months ($888 when that annual plan is billed after the introductory month), not paying $74 each month. Medication is billed separately. Ro says it refunds the $39 if you're not eligible. Check the selected plan's renewal and refund terms before prepaying. Prices checked October 14, 2026, on Ro's pricing page.²⁴

The free checker needs your insurance details and sends a report by email. It does not prescribe medicine or submit a treatment request. It currently excludes Wegovy pills, Foundayo pills, and Zepbound KwikPens. Ro says patients with Medicaid and some other government-funded plans are not eligible for treatment; Medicare and TRICARE readers should start with their own plan and clinician for covered care rather than assume Ro can bill those benefits.²²²³

Have commercial insurance and want to see what your plan says about those pens before deciding whether to wait? Request the free report; it is not a treatment approval.

Not sure whether insurance, cash pay, a pill, or a shot fits you best? Answer a few quick questions and compare available GLP-1 paths and providers for your situation.

---

What the retatrutide trials found, in plain English

Across five Phase 3 trials, Lilly's efficacy analyses estimated about 17% to 29% average weight loss in the 12 mg groups, depending on who was in the study and for how long. The diabetes trials had smaller weight-loss averages than the trials without diabetes. Stomach and gut side effects were the most common, and some people stopped treatment because of adverse events.^2514162627

These are group averages from separate trials with different people and lengths. Don't rank one row against another. Unless marked “counting everyone” or “treatment-regimen,” numbers use the efficacy analysis. Stopping treatment because of an adverse event is not the same as leaving the study for any reason, and an adverse event is not always caused by the medicine. Sources: TRIUMPH-1, TRIUMPH-2, TRIUMPH-3 sponsor results, TRIUMPH-4 sponsor results, and TRANSCEND-T2D-1.

Why every trial seems to have two numbers

Picture a class where some students drop out halfway. One way to grade the class counts everyone who started, dropouts included. The other estimates how the class would have done if nobody quit.

Trials do the same thing. In TRIUMPH-1, counting everyone randomized gave 25.0% at 80 weeks on 12 mg. Estimating "if everyone stayed on it" gave 28.3%. The NEJM paper leads with 25.0%. Lilly's press release led with 28.3%. Both are real. They answer different questions.

The exact terms are treatment-regimen estimand (the result regardless of treatment stopping or other weight treatment) and efficacy estimand (the estimated result if assigned treatment continued, with allowed dose changes, and without prohibited weight treatments). An estimand defines what effect the analysis is trying to measure. “Counting everyone” includes statistical handling of missing measurements; it does not mean every person had a final weigh-in. It is not a real-world guarantee.²²⁵

You'll also see "30%." That came from a selected TRIUMPH-1 extension with 532 participants who had a starting BMI of 35 or higher, finished 80 weeks, tolerated their assigned dose, and kept going to 104 weeks. The 30.3% efficacy result was for the original 12 mg group within that extension, not all 532 people. It's not what a typical person starting out should expect.²⁵

For every dose and the pounds math, see our retatrutide weight loss results. For how to read these numbers yourself, see placebo-adjusted weight loss explained and how to read GLP-1 clinical trials.

Beyond the scale

Peer-reviewed or press release?

A peer-reviewed journal paper has outside experts review the submitted methods and results. A press release is the company's own summary. Both matter. They're not the same strength of evidence. A paper about a study's design is not the same as a paper reporting its results.²⁸⁵

Does this prove retatrutide beats Zepbound?

No. These five Phase 3 studies tested retatrutide against placebo, not against Zepbound, so they can't crown a winner. TRIUMPH-5 is the direct comparison with tirzepatide; no results were identified in the registry and sponsor sources checked.⁴

---

What the trials showed about safety

The most common side effects were nausea, diarrhea, constipation, and vomiting. A skin-sensation effect called dysesthesia also showed up more than on placebo. Retatrutide has no FDA-approved prescribing label yet; these are trial observations, not proof that products sold online are safe.²⁵³

Source: Lilly's TRIUMPH-1 release, May 21, 2026. In TRIUMPH-2 (people with diabetes), dysesthesia was 7.3% on 12 mg vs 0.7% on placebo. Full trial-by-trial rates: retatrutide side effects.²⁵¹⁴

The trial drug is not the "Reta" sold online

The FDA says retatrutide cannot be used in compounding under federal law and has not been found safe and effective for any condition. It has warned telehealth companies, ingredient sellers, and sellers of "research use only" retatrutide. A vial bought online is not a spot in a Lilly trial, and nobody can promise what's in it.

On August 12, 2026, Lilly announced six lawsuits against U.S. sellers of unapproved retatrutide products. The cases include sellers calling their products “research use only.” That label does not make a product suitable for human use.²⁹³

If you used something labeled retatrutide and are worried about an exposure or reaction, call U.S. Poison Control at 1-800-222-1222 right away. Call 911 for collapse, a seizure, trouble breathing, or someone who cannot be awakened. Keep the vial and packaging for the poison specialist or treating clinician; do not delay emergency care to find them.³⁰

More: how to avoid fake GLP-1 medications and our compounded GLP-1 enforcement tracker.

---

When will retatrutide be approved?

No approval date has been announced. Lilly says it plans to submit a Biologics License Application to the FDA in the first quarter of 2027. That is an application for approval, not an approval date. FDA review comes after submission; no launch date or official commercial price has been announced.¹⁴³

The order goes like this: positive trials, then the filing, then FDA review, then a decision, then pharmacies and insurers. Retatrutide is on step two's doorstep. A study's end date doesn't predict an approval date.

How FDA review works: FDA approval process for obesity drugs and priority vs standard review. Price guesses and why they're guesses: retatrutide cost predictions.

---

What we actually verified

We retrieved the 33 records returned by the ClinicalTrials.gov retatrutide intervention search and checked the primary sources on October 14, 2026. Registry statuses, journal results, and company-reported results are labeled separately. We did not call study sites, judge anyone's eligibility, confirm individual study costs, complete a paid checkout, or test any product.

Checked October 14, 2026

• All 33 returned ClinicalTrials.gov records (32 studies + 1 expanded access): status, enrollment, dates, and sponsor. We also checked study arms for the comparison filter.
• Full posted eligibility for SYNERGY-Outcomes, NCT07467447, and the expanded-access program; SYNERGY's listed locations and contacts.
• The accessible journal abstracts for TRIUMPH-1, TRIUMPH-2, TRANSCEND-T2D-1, and the earlier Phase 2 trials, plus publication records for the early clinical papers linked above. These were not full reviews of paywalled papers.
• Lilly's results releases for TRIUMPH-1 (May 21, 2026), TRIUMPH-2 and -3 (July 23, 2026), TRIUMPH-2 detail (September 29, 2026), TRIUMPH-4 (December 11, 2025), and TRANSCEND-T2D-1 (March 19, 2026). We used Lilly's own issued release on PR Newswire where its investor page would not load.
• FDA's page on unapproved GLP-1 drugs (content dated October 1, 2026), its expanded-access information, Zepbound's prescribing information, and Poison Control's emergency instructions.
• Ro's current public pricing, insurance policies, and free coverage-checker description. We checked the offer, not anyone's actual benefits or final checkout bill.

What we couldn't confirm

• Whether any particular site is screening this week. Only the site can tell you.
• Who supplies NCT07467447's study medicine, or whether Lilly is involved.
• Individual study costs, payments, or travel reimbursement.
• Exact release dates for TRIUMPH-5 or the TRANSCEND-T2D-2 and -3 results.
• Full-paper details behind journal paywalls, or every unindexed results publication.
• The final renewal and prepaid-refund terms for a selected Ro checkout plan. No pro-rated refund is promised here.

Small mismatches we're showing, not hiding: the registry lists 2,335 people for TRIUMPH-1 and 1,946 for TRIUMPH-3; Lilly reported 2,339 and 1,949 randomized. Copies of Lilly's TRIUMPH-4 release show two different study numbers; we use the registry's, NCT05931367.

We don't sell peptides, and we have no relationship with any peptide seller. No physician reviewed this version of the page. Found an error? Our corrections page explains how we fix and log it.

---

Retatrutide clinical trials FAQ

What is the purpose of the retatrutide trials?

To find out whether retatrutide safely helps with weight, type 2 diabetes, fatty liver disease, knee and back pain, sleep apnea, and heart and kidney risk. Each trial has a main question and supporting outcomes. Together they inform whether regulators should approve particular uses.¹

How many people were in the retatrutide trials?

The five Phase 3 trials that have reported randomized 6,422 people: 2,339 in TRIUMPH-1, 1,152 in TRIUMPH-2, 1,949 in TRIUMPH-3, 445 in TRIUMPH-4, and 537 in TRANSCEND-T2D-1. The 32 registry records' enrollment counts total 27,224, mixing actual and planned enrollment. Those totals include placebo and other-drug groups, not just people given retatrutide, and are not a verified count of unique people who completed treatment.^1214162627

Is retatrutide available outside the TRIUMPH trials?

TRIUMPH is not the whole program. Other studies include SYNERGY-Outcomes, TRANSCEND-T2D, and early-phase research. Outside trials, a narrow expanded-access program requires your own doctor's request and all its criteria. There is no ordinary retail prescription path, and FDA says retatrutide cannot be compounded.¹¹⁹³

Where can I check current retatrutide trial status?

On ClinicalTrials.gov and Lilly's trial finder. Our tracker above separates each record's update date from the date we checked it. A study-wide status still needs a local-site check.

How do I get into a retatrutide clinical trial?

Find a study that's recruiting, read its record, and contact a listed site to ask whether it's screening new people. As of October 14, 2026, the only Lilly study listed as recruiting in this tracker is SYNERGY-Outcomes, for high-risk fatty liver disease. The study team decides who qualifies.¹¹²

Will I definitely get retatrutide if I join?

No. Many studies include placebo, and some compare retatrutide with another medicine. TRIUMPH-9 is one example where everyone is assigned retatrutide, but it is closed to new people. Ask the team about assignment in the exact study you are considering.¹¹⁷

Can I join a trial while I'm on Zepbound or Wegovy?

It depends on the study, not a general waiting period. The Hudson record excludes recent weight-loss medicine use; the now-closed TRIUMPH-7 record has its own 90-day rule. Have the study team review your medicines, and never stop a prescription to chase a trial spot without your prescriber.¹⁵⁶

Is expanded access the same as joining a trial?

No. It's a separate path outside any trial, with five strict rules, and your treating doctor has to make the request. Meeting the rules still doesn't guarantee access.¹⁹²⁰

Are the retatrutide results peer-reviewed?

Some are. TRIUMPH-1 (NEJM) and TRIUMPH-2 (The Lancet) were published online September 29, 2026; TRANSCEND-T2D-1 appeared online in The Lancet on June 6, 2026. For TRIUMPH-3 and TRIUMPH-4, this page cites company results; no peer-reviewed results paper was identified in the check.²³¹³²

Is retatrutide better than Zepbound?

A direct verdict is not available from the results checked for this page. TRIUMPH-5 compares retatrutide with tirzepatide; its main data collection is estimated to finish in November 2026, with study completion estimated in December. Neither date is a promised results-release date.⁴

Are "completed enrollment" and "completed" the same?

No. "Completed enrollment" means the study stopped taking new people but may still be running. "Completed" means the study is finished.

When will retatrutide be FDA-approved?

No approval date has been announced. Lilly plans to file in the first quarter of 2027, and FDA review comes after submission.¹⁴

Is "Reta" or research-use retatrutide the same as the trial drug?

A retail product labeled “Reta” is not an approved medicine, and its label does not establish that it is the product used in Lilly's trials. FDA warns that research-use products sold for human use have unknown quality and may be harmful. Do not treat trial findings as evidence for a seller's vial.³

What happens to my treatment when a study ends?

Ask before you join. Don't assume free medicine continues. SYNERGY-Outcomes offers an optional extension to eligible people, but that isn't a promise for everyone or every study.¹²

Still not sure which GLP-1 path fits you? Take The RX Index's free Find My GLP-1 Path quiz — about 2 minutes, no signup.

---

Checked October 14, 2026. Publication dates and registry-update dates below are separate from that check date. Journal citations identify the accessible material reviewed; a linked full paper is not a claim that we reviewed its paywalled contents.

Sources

1. ClinicalTrials.gov. Retatrutide intervention search, API v2 query, and the 32 individual study records linked above. Retrieved October 14, 2026: 32 interventional studies and one expanded-access record. Each row retains its registry update date.
2. Jastreboff AM, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. New England Journal of Medicine, published online September 29, 2026. PubMed abstract checked; full paywalled paper not reviewed.
3. U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, content dated October 1, 2026. Retatrutide approval status, federal compounding restriction, and warnings about research-use products sold for human use.
4. ClinicalTrials.gov. TRIUMPH-5, NCT06662383, updated July 20, 2026. Primary completion estimated November 2026; study completion estimated December 2026. Neither is a results-publication date.
5. TRANSCEND-CKD rationale, design and baseline characteristics, Nephrology Dialysis Transplantation. DOI: 10.1093/ndt/gfaf230. This is not an outcome-results paper.
6. ClinicalTrials.gov. TRIUMPH-7, NCT07035093, updated September 25, 2026; Lilly TRIUMPH-7 page. Active, not recruiting / completed enrollment; posted medication exclusions are study-specific.
7. The RX Index. Find My GLP-1 Path and the current sitewide tool description: suggested paths/providers and pricing to review; free, about 2 minutes, no signup. It does not check actual plan coverage or clinical eligibility.
8. Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. NEJM, 2023. PubMed abstract checked.
9. Rosenstock J, et al. Retatrutide for people with type 2 diabetes: Phase 2 trial. The Lancet, 2023. DOI: 10.1016/S0140-6736(23)01053-X. The abstract reports a 2.02-percentage-point A1C decrease at 24 weeks in the 12 mg group.
10. Coskun T, et al. LY3437943: From discovery to clinical proof of concept. Cell Metabolism, published online August 18, 2022. Early single-dose human study and preclinical work.
11. Urva S, et al. LY3437943 in people with type 2 diabetes: Phase 1b trial. The Lancet, published online October 27, 2022. Linked by the NCT04143802 record.
12. ClinicalTrials.gov. SYNERGY-Outcomes, NCT07165028, updated October 8, 2026. Posted protocol, eligibility, arms, contacts, and locations checked. The 35-state count is our count of distinct U.S. states in the listed locations, not 35 confirmed recruiting states.
13. ClinicalTrials.gov. TRANSCEND-T2D-2, NCT06260722, updated September 28, 2026, and TRANSCEND-T2D-3, NCT06297603, updated July 20, 2026. Primary completion: August 27, 2026 (actual) and October 2026 (estimated), respectively.
14. Eli Lilly. TRIUMPH-2 detailed results and planned regulatory submission, September 29, 2026. Full Lilly-issued release on PR Newswire; Lilly investor-page version.
15. ClinicalTrials.gov. NCT07467447, updated March 12, 2026. Listed sponsor: Hudson Biotech. The registry listing was checked; medicine supply, local authorization, and any Lilly relationship were not independently confirmed.
16. Eli Lilly. TRIUMPH-2 and TRIUMPH-3 topline results, July 23, 2026. Full sponsor release. The TRIUMPH-3 results do not establish a reduction in major cardiovascular events.
17. ClinicalTrials.gov. TRIUMPH-9, NCT07357415, updated June 9, 2026. The registered arms use different retatrutide escalation schemes, not placebo.
18. U.S. Department of Health and Human Services, Office for Human Research Protections. Questions to Ask About Volunteering for a Research Study. Questions about treatment assignment, current care, costs, payments, risks, and participation.
19. ClinicalTrials.gov. Pre-approval Expanded Access of Retatrutide, NCT07629401, updated August 6, 2026. Physician-initiated program with all five inclusion criteria, a medical-contraindication exclusion, and geography/supply/individual-review limits.
20. U.S. Food and Drug Administration. Expanded Access. Patient and physician responsibilities and the distinction between access outside a trial and ordinary commercial prescribing.
21. Eli Lilly. Zepbound FDA-approved prescribing information, revised August 2026. Adult indications, clinical-study BMI ranges, contraindications, and pregnancy warning. This page does not give dosing or switching instructions.
22. Ro. GLP-1 Insurance Coverage Checker. Current free-report service, supported pen products, exclusions, required information, and limits; checked October 14, 2026.
23. Ro. How insurance works with the Ro Body membership. Paid insurance-concierge scope, separate medication costs, and government-plan eligibility limits; checked October 14, 2026.
24. Ro. Weight loss program pricing. Introductory and ongoing membership pricing and separate medication costs; checked October 14, 2026. $888 is our calculation of 12 × $74, not an all-in treatment price.
25. Eli Lilly. TRIUMPH-1 topline results, May 21, 2026. Full sponsor release, including both analyses, adverse-event rates, and the selected 104-week extension.
26. Eli Lilly. TRIUMPH-4 topline results, December 11, 2025. Full sponsor release. Correct registry identity: NCT05931367.
27. Eli Lilly. TRANSCEND-T2D-1 topline results, March 19, 2026. Full sponsor release; Lilly-issued PR Newswire version.
28. Rationale and design of the TRIUMPH program. Diabetes, Obesity and Metabolism. DOI: 10.1111/dom.70209. This design publication is not a TRIUMPH-3 or TRIUMPH-4 results paper.
29. Eli Lilly. Lilly calls on online platforms, payment companies and regulators to stop illegal sales of investigational retatrutide, August 12, 2026. Six lawsuits announced; this is not a claim that the cases were decided in Lilly's favor.
30. National Capital Poison Center. Need immediate assistance?. U.S. poison advice at 1-800-222-1222; emergency symptoms requiring 911.
31. Bellido V, et al. TRIUMPH-2 journal abstract. The Lancet, published online September 29, 2026; print issue October 10, 2026. DOI: 10.1016/S0140-6736(26)01861-1. Abstract checked; full paywalled paper not reviewed.
32. Bajaj HS, et al. TRANSCEND-T2D-1 journal abstract. The Lancet, published online June 6, 2026; print issue June 13, 2026. DOI: 10.1016/S0140-6736(26)00967-0. Abstract checked; full paywalled paper not reviewed.